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Ablation of CD8α+ dendritic cell 
mediated cross-presentation does 
not impact atherosclerosis in 
hyperlipidemic mice
Bart Legein1, Edith M. Janssen2, Thomas L. Theelen1, Marion J. Gijbels1,4, Joep Walraven1, 
Jared S. Klarquist2, Cassandra M. Hennies2, Kristiaan Wouters3, Tom T.P. Seijkens4, 
Erwin Wijnands1, Judith C. Sluimer1, Esther Lutgens4,5, Martin Zenke6, Kai Hildner7, 
Erik A.L. Biessen1 & Lieve Temmerman1
Clinical complications of atherosclerosis are almost exclusively linked to destabilization of the 
atherosclerotic plaque. Batf3-dependent dendritic cells specialize in cross-presentation of necrotic 
tissue-derived epitopes to directly activate cytolytic CD8 Tcells. The mature plaque (necrotic, 
containing dendritic cells and CD8 Tcells) could offer the ideal environment for cross-presentation, 
resulting in cytotoxic immunity and plaque destabilization. Ldlr−/− mice were transplanted with 
batf3−/− or wt bone marrow and put on a western type diet. Hematopoietic batf3 deficiency sharply 
decreased CD8α+ DC numbers in spleen and lymph nodes (>80%; P < 0,001). Concordantly, 
batf3−/− chimeras had a 75% reduction in OT-I cross-priming capacity in vivo. Batf3−/− chimeric mice 
did not show lower Tcell or other leukocyte subset numbers. Despite dampened cross-presentation 
capacity, batf3−/− chimeras had equal atherosclerosis burden in aortic arch and root. Likewise, 
batf3−/− chimeras and wt mice revealed no differences in parameters of plaque stability: plaque 
Tcell infiltration, cell death, collagen composition, and macrophage and vascular smooth muscle cell 
content were unchanged. These results show that CD8α+ DC loss in hyperlipidemic mice profoundly 
reduces cross-priming ability, nevertheless it does not influence lesion development. Taken together, 
we clearly demonstrate that CD8α+ DC-mediated cross-presentation does not significantly contribute 
to atherosclerotic plaque formation and stability.
Immune responses play a significant role in the pathophysiology of atherosclerosis1,2. They offer a 
promising new therapeutic angle to directly touch on pathogenic mechanisms of cardiovascular dis-
ease. Necrosis - a prime hallmark of clinical atherosclerosis - was recently linked to immunity. Necrotic 
tumor cell-derived epitopes are able to elicit a strong cytolitic immune response, allowing tumor elimina-
tion3,4. Key to this finding is a process called cross-presentation: direct presentation of exogenous antigen 
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on an MHCI molecule followed by a potent CD8+ Tcell activation5. Mouse dendritic cells (CD8α + or 
CD103+ DCs) appear to be highly efficient cross-presenting cells6, uniquely qualified to cross-present 
dead cell-associated antigens7. Identification of their human counterparts8–12 emphasizes the importance 
of cross-presentation in human health and disease.
In a mature atherosclerotic plaque, necrotic cell or tissue-associated epitopes, dendritic cells13 and 
CD8+ Tcells14,15 are abundantly present and in close contact. Significantly more DCs are found in 
rupture-prone, vulnerable plaques16, and CD8+ Tcells increase to up to 50% of the total leukocyte pool 
in human advanced plaques17, linking both DC and cytotoxic Tcell presence to plaque stability. In addi-
tion, CD8+ Tcells isolated from human plaque atherectomy specimens are highly activated, much more 
so than plaque CD4+ Tcells or Tcells isolated from the blood of the same patients18. Moreover, reflective 
of plaque-directed immunity, different auto-antigens are identified targets of immune responses in ather-
osclerosis. Oxidized low density lipoprotein (oxLDL) is the most well described19, but Tcells isolated from 
patients with advanced atherosclerosis also respond to F-actin, a known target in necrosis-associated 
cross-presentation20,21. Lastly, a recent study has demonstrated that cytotoxic CD8+ Tcells promote devel-
opment of a vulnerable atherosclerotic plaque in mice, implicating cytolytic Tcell immunity in plaque dest-
abilization22. Combining these arguments led to the following intriguing hypothesis: Cross-presentation, 
by mounting a cytolytic CD8+ Tcell immune response against cap/plaque material, might be crucial in 
the destabilization of the advanced plaque which generally precedes plaque rupture, thrombi formation 
and infarcts.
However, complete knockout of the CD8 gene in atherosclerosis-susceptible ApoE−/− mice, presum-
ably affecting both CD8α + DC and CD8+ Tcell function, did not lead to the expected reduction in 
atherosclerosis23. Similarly, ApoE−/− mice deficient in Antigen Peptide Transporter 1 (TAP1, involved 
in antigen cross-presentation), displayed an equivalent atherogenic response24. Moreover, MHCI knock-
out (KO) mice on a 15 week high fat diet showed increased plaque formation (+ 150%), suggesting 
that MHCI-dependent antigen presentation, inducing cytotoxic CD8+ Tcells, is atheroprotective25. 
Possible protection by cross-presenting DCs was also observed in the flt3−/− ldlr−/− mouse, where 
depletion of Flt3L-dependent DCs resulted in aggrevated atherosclerosis26. Unfortunately, each of these 
studies implies severe modifications of the entire immune system, which greatly impedes assessment 
of purely cross-presentation related effects. Thus, evidence for a direct role of cross-presentation in a 
“plaque-targeted” immune response remains circumstantial and inconclusive.
This study aimed at dissecting the mechanism behind the strong cytotoxic T cell response in advanced 
atherosclerosis. We hypothesized that cross-presentation of necrotic plaque epitopes will prime CD8+ 
Tcells to attack plaque components. In order to investigate this, we took a loss-of-function approach 
making use of chimeric batf3−/− mice, which specifically lack CD8α + DCs and CD103+ DCs, the most 
important cell populations for cross-presentation27,28. Unexpectedly, the severe defect in cross-presentation 
in batf3−/− chimeras did not translate into apparent differences in CD8+ Tcell numbers, nor did it signif-
icantly affect atherosclerotic plaque size or composition.
Results
Cross-presentation markers increase in advanced atherosclerotic plaques. First, to evaluate 
the validity for a role of cross-presentation in plaque destabilization, expression of key cross-presentation 
markers in human and mouse atherosclerotic lesions was examined. We investigated RNA expression 
levels of Thrombomodulin, Basic leucine zipper transcription factor, ATF-like 3, Interferon regulatory 
factor 8 and nectin-like molecule 2 (BDCA3, Batf3, IRF8 and Necl2: markers of the main cross-pre-
senting DC population in humans29) and of Antigen Peptide Transporter 1, Ras-related protein 11b, 
and Adipocyte Differentiation-related Protein (TAP1, Rab11b and ADFP: involved in antigen processing 
and presumed cross-presentation pathways30–32) in early, advanced and unstable human plaque mate-
rial. BDCA3, IRF8 and ADFP were all significantly upregulated in ruptured plaques compared to initial 
lesions, and Batf3, TAP1 and Necl2 all showed a similar trend (Fig.  1a). Rab11b expression did not 
correlate with plaque progression (data not shown). XCR112 and CD11c immunohistochemical staining 
revealed few cross-presenting cells were present in advanced and unstable human plaques, while they 
could not be found in early plaques (Fig. 1b, Sup. Fig. 1a). In mouse advanced plaques, Rab11b, TAP1 
and XCR1 RNA expression levels were increased compared to early plaques (Fig. 1c). Similar to human 
plaques, cross-presenting DCs were scarce in mice and only found in advanced plaques (Fig.  1d, Sup. 
Fig. 1b). Overall, RNA expression patterns of cross-presentation markers correlated with a phenotype of 
increased plaque burden and instability, and cross-presenting cells were almost exclusively found in the 
more advanced plaque types, pointing to a potential role for cross-presentation in plaque progression 
and destabilization in human and mouse atherosclerosis.
Cross-presentation occurs under hyperlipidemic conditions. Hyperlipidemia is known to affect 
the behavior and activation state of many immune cell types1, and could thus influence the efficacy of 
immune responses mediated by these cells. Therefore, efficiency of cross-presentation in hyperlipidemic 
conditions was evaluated. Ldlr−/− mice on chow or western type diet (WTD, 0.25% cholesterol) were 
injected with fluorescently labeled Tcells isolated from OT-I mice. These cells express a T cell receptor 
(TCR) engineered to recognize a specific chicken ovalbumin (OVA) antigen (SIINFEKL) only when it is 
presented in context of mouse MHCI-Kb 33. Mice also received OVA-expressing necrotic cells, which are 
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taken up and processed by endogenous dendritic cells. Only cross-presentation of the OVA epitope leads 
to direct activation and proliferation of the OT-I Tcells. In chow-fed mice most OT-I Tcells had prolif-
erated. OT-I Tcell mitogenic capacity was unaffected in WTD fed mice, establishing normal, functional 
cross-presentation is able to occur in a hyperlipidemic environment (Fig. 2a,b).
Batf3-dependent DCs are efficiently depleted in atherosclerotic batf3−/− chimeric mice. Local 
inflammatory processes are very important in atherosclerosis. To ensure the effectiveness of our planned 
approach we tested whether vascular dendritic cells could be successfully depleted and reconstituted by 
a bone marrow transplant experiment. CD45.2 ldlr−/− mice were lethally irradiated and received bone 
marrow from CD45.1 mice. Without induction of atherosclerosis, dendritic cells in the aortas of the 
Figure 1. Expression of cross presentation markers in human and mouse atherosclerosis. (a) Total RNA 
was isolated from fresh-frozen human atherosclerotic plaques. Real-time PCR results of expression levels 
of BDCA3, IRF8, ADFP, Batf3, TAP1 and Necl2 are shown as mean ± SEM. All expression levels were first 
normalized for levels of β -actin expression, and are depicted as fold induction when compared to expression 
levels in early plaques. Samples were grouped based on histological qualification of plaque stage according to 
Virmani et al.57. Early: Intimal Thickening/ Pathological Intimal Thickening (n = 5), Advanced: Thick/Thin 
Fibrous Cap Atheroma (n = 6), Unstable: Intra Plaque Hemorrhage (n = 5). *p < 0.05, ***p < 0.001.  
(b) Representative images of frozen human carotid plaque sections (n = 8–10) doublestained with antibodies 
against XCR1 (green) and CD11c (red) to identify cross-presenting DCs. Colocalization was determined 
using a Nuance Spectral Imaging System and is indicated in yellow. (c) Total RNA was isolated from fresh-
frozen mouse aorta’s. Real-time PCR results of expression levels of Rab11b, TAP1 and XCR1 are shown as 
mean ± SEM. All expression levels were first normalized for levels of GAPDH expression, and are depicted 
as fold induction when compared to expression levels in early plaques. Early: 8 wk old C57Bl6 mice (n = 6), 
Advanced: > 35 wk old C57Bl6 ApoE−/− mice (n = 5) (d) Representative images of frozen mouse aortic root 
sections doublestained with antibodies against CD8α (red) and CD11c (blue) to identify cross-presenting 
DCs. Nuclei were lightly counterstained with MethylGreen. Arrow: doublestained cell.
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transplanted mice were very scarce (0.8% of immune cells), and they were completely ablated 4 days 
after irradiation treatment (Sup. Fig. S2a, b). In addition, we could show by flow cytometry that 6 weeks 
after irradiation, only 1.3% of immune cells in the vessel wall are CD45.2 positive (i.e. from the host), 
instead they were almost exclusively CD45.1 positive, demonstrating effective reconstitution of the resi-
dent immune cells in the vessel wall by donor cells (Sup Fig S2e, f). Antibody stainings against CD45.1 
and CD45.2 confirm the flow cytometry results (Sup Fig S2g). We therefore concluded that we could 
use a bone marrow transplantation approach to efficiently disturb cross-presentation in atherosclerosis.
In order to investigate the relative contribution of Batf3-dependent cross-presentation in development 
and progression of atherosclerosis, lethally irradiated ldlr−/− mice were reconstituted with bone marrow 
from batf3−/− mice or wild type (wt) control mice. Batf3−/− mice selectively lack CD8α + and CD103+ 
DCs and are not able to effectively cross-present necrotic cell exposed epitopes27. After recovery, mice 
were given a Western type diet (WTD) for 10 weeks to induce atherosclerotic plaque formation (Fig. 3a). 
Batf3−/− transplanted ldlr−/− mice (hereafter batf3−/− chimeras) showed more than 80% reductions in 
CD8α + DCs in spleen (Fig.  3b,c) and lymphoid organs (data not shown). As expected, CD103+ DCs 
were equally diminished by Batf3 deficiency (Fig. 3d), because their development is also Batf3 depend-
ent28. Illustrating specificity of the batf3−/− model, other leukocyte populations in blood (Sup. Fig. S3), 
spleen (Sup. Fig. S4) or peripheral lymph nodes (Sup. Fig. S5) were not affected. At sacrifice, batf3−/− chi-
meras did not differ in body weight from mice transplanted with wt bone marrow (Fig. 3e). Both groups 
showed equivalent and significant increases in plasma cholesterol (Fig.  3f). These parameters indicate 
efficient induction of the atherosclerosis model.
We next investigated if other DC populations with, albeit lower, capacity to cross-present might have 
expanded to compensate for the loss of Batf3-dependent DCs. Merocytic DCs (mDCs) can cross-present in 
a context of diabetes34, and even plasmacytoid DCs (pDCs) were reported to have some cross-presentation 
abilities35. However, no differences were found in mDC or pDC numbers in spleen (Sup. Fig. S6a, b) and 
lymph nodes (data not shown). Recently, a subset of CD169+ macrophages (CD11b+ CD11c+ CD169+ 
F4/80+) efficiently cross-presenting tumor antigens was described in spleen36. This population did not 
change in spleens of mice on a normal diet compared to mice on a western type diet (Sup. Fig. S6c), 
rendering their role in atherosclerosis-related cross-presentation not very likely. In summary, we did not 
identify other DC or DC-like populations likely to have taken over cross-presentation from the depleted 
CD8α + DCs in this atherosclerosis model.
Hyperlipidemic CD8α+ DC depletion profoundly affects systemic cross-presentation abil-
ity. In accordance with the severe CD8α + DC depletion observed, hematopoietic Batf3 deficiency in 
atherosclerotic mice had a profound effect on cross-presentation. Batf3−/− chimeras and control mice 
were injected with fluorescently labeled OT-I Tcells and with necrotic OVA-expressing cells as described 
above. OT-I Tcell proliferation was severely diminished from 80% in control mice to 23% in batf3−/− 
animals (Fig.  4a,b). Interestingly, the number of residual CD8α + DCs in batf3−/− chimeras correlated 
with the cross-presenting capacity (r2 = 0.89, p = 0.01), establishing the significant role of this DC subset 
in cross-presentation, even in a hyperlipidemic setting (Fig. 4c).
Figure 2. Cross-presentation occurs under hyperlipidemic conditions. Ldlr−/− mice (n = 3) on a 
normal chow diet or fed a Western type diet (WTD) for three weeks were iv injected with irradiated 
OVA-expressing splenocytes and CFSE-labeled OT-I Tcells. After 72 hrs, spleens were harvested and cross-
presentation was assessed by flow cytometry, quantifying the proportion of proliferating OT-I Tcells (cells 
with a diluted CFSE signal) within the total OT-I Tcell population, normalized for amount of injected cells. 
(a) Bar graph of proliferated OT-I Tcells (% of total OT-I Tcells) in spleen of chow or WTD-fed ldlr−/− mice. 
(b) Representive CFSE dilution peaks of the OT-I Tcell population. Data are presented as mean ± SEM.
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CD8α+ dendritic cell depletion does not affect atherosclerosis. First, we analyzed aortic roots 
from batf3−/− chimeras and control mice which had been fed a normal chow diet to evaluate whether 
CD8α + DC depletion affected initial plaque formation. However, while some mice exhibited very small 
initial lesions, plaque sizes of both groups were similar (Sup. Fig. 7). Next, the effect of significantly ham-
pered cross-presentation ability on atherosclerosis could be analyzed. Unexpectedly, neither advanced 
plaques in the aortic root nor initial plaques in brachiocephalic artery showed differences in plaque size, 
necrotic core size or necrotic core percentage between batf3−/− chimeras and control mice (Fig.  5a,b). 
Plaques from batf3−/− chimeras and control mice also contained the same amount of macrophages 
(Fig. 6a,b: first panel). In addition, features of plaque stability were similar in both groups, as we observed 
no changes in vascular smooth muscle cell content or collagen (Fig. 6a,b: second and third panel, Sup. 
Figure 3. Batf3 deficiency results in severe CD8α+ DC depletion in the atherosclerosis model.  
(a) Lethally irradiated ldlr−/− mice were reconstituted with wt (n = 15) or batf3−/− (n = 12) bone marrow, 
and after 6 weeks recovery, put on a WTD containing 0,25% cholesterol for 10 weeks. (b) Representative 
flow cytometry gating of CD8α + DC population (Lin−, CD11chigh, MHCIIhigh, CD8α +). (c) Bar graph of 
CD8α + DCs as percentage of cDCs. (d) Bar graph of CD103+ DCs as percentage of cDCs. (e) Body weight 
at sacrifice. (f) Total cholesterol content in serum at sacrifice. Data are presented as mean ± SEM, **p < 0,01, 
***p < 0,001.
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Fig. S9). To exclude unknown local environmental or other contributory factors, we repeated the study in 
the same setup in the laboratory of our collaborator Prof. Dr. E. Janssen, Cincinnati, US, with ldlr−/− and 
batf3−/− mice from Jackson Laboratories. Again, cross-presenting CD8α + DCs were severely depleted in 
batf3−/− chimeras, yet no differences were seen in atherosclerosis phenotype (Sup. Fig. S8). Thus, CD8α + 
DC depletion does not alter plaque size or the stable plaque phenotype in atherosclerotic mice.
Tcell activation is unchanged in CD8α+ DC depleted atherosclerotic mice. We postulated 
that cross-presentation of plaque epitopes would lead to expansion of cytolytic plaque-targeted CD8+ 
Tcells, resulting in plaque destabilization. However, consistent with the observations regarding plaque 
size or phenotype, Tcell content and plaque apoptosis did not differ between batf3−/− chimeric mice 
and control mice (Fig. 6a,b: fourth and fifth panel). Moreover, total, CD4+ and CD8+ Tcell numbers in 
blood, spleen and peripheral lymph nodes and were not changed by batf3 deficiency (Sup. Fig S3-5). 
As we would primarily expect effects on T cell biology at the site of atherosclerosis, we also analyzed 
T cell phenotype in the aorta-draining lymph nodes (lnn. mediastinalis dorsalis, strongly enlarged in 
atherosclerosis) but no relevant differences in the proportion of regulatory T cells (Fig. 7a) were found. 
Naïve (CD44low, CD62Lhigh), effector memory (CD44high,CD62Llow) and central memory Tcell counts 
(CD44high, CD62Lhigh) in the aorta-draining lymph nodes were not affected by Batf3 deficiency (Fig. 7b,c) 
as well. These data suggest that cross-presentation does not play an active role in the clonal expansion of 
atherosclerosis-relevant Tcells, neither locally in the aorta-draining lymph node, or systemically in the 
lymphoid organs.
Figure 4. Cross-presentation is affected in batf3−/− chimeric mice. Batf3−/− chimeric or wt ldlr−/− 
mice (n = 7) were iv injected with necrotic OVA-expressing splenocytes and CFSE-labeled OT-I T cells. 
After 72 hrs, spleens were harvested and cross-presentation was assessed by flow cytometry, quantifying 
the proportion of proliferating OT-I Tcells (cells with a diluted CFSE signal) within the total OT-I Tcell 
population, normalized for amount of injected cells. (a) Bar graph of proliferated OT-I Tcells (% of total 
OT-I Tcells) in spleen. (b) Representive CFSE dilution peaks of the OT-I Tcell population. (c) Correlation 
analysis between amount of residual CD8α + DCs and the remaining cross-presentation capacity in batf3−/− 
chimeras. Data are presented as mean ± SEM, ***p < 0,001.
www.nature.com/scientificreports/
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Discussion
Cytotoxic immunity is emerging as a key process in advanced atherosclerosis22, but its actors and triggers 
are hitherto largely unknown. We opted for cross-presentation as plausible candidate, considering that all 
components for effective cross-presentation are present in the advanced atherosclerotic plaque and that 
several genes involved in cross-presentation were more expressed in ruptured compared to early athero-
sclerotic lesions of CVD patients. Moreover, exposure to high LDL/VLDL levels in advanced atheroscle-
rosis would most likely not interfere with the cross-presentation machinery, as we showed that systemic 
cross-presentation efficacy in mice was not affected by hyperlipidemia. Likewise, CD11c+ DCs under 
conditions of hyperlipidemia take up and process antigens normally, and are able to activate Tcells37.
Cross-presentation of necrotic plaque epitopes could theoretically take place in the plaque itself, 
in analogy to antigen presentation by DCs to CD4+ T cells38, or in plaque-draining lymphoid organs. 
CD103+ DCs increase in the atherosclerotic aortic wall26 and might activate CD8+ T cells in situ or 
migrate to adjacent lymph nodes. Alternatively, CD8α + DCs could cross-present shed plaque material 
in lymphoid organs, as they very efficiently do so with dying cell particles during intracellular pathogen 
infections39, upon which activated CD8+ T cell clones may travel to the plaque. Here, both routes of 
cross-presentation were ablated by depleting CD8α + DC and CD103+ DC in a well-established mouse 
model of atherosclerosis. Concordant with previous studies in whole-body batf3−/− mice27,28, chimeric 
batf3−/− mice exclusively targeted the aforementioned Batf3 dependent cell populations, leaving other 
leukocyte subsets unaffected. In addition, cross-presentation capability – again similar to the full batf3−/− 
phenotype – was profoundly reduced in batf3−/− chimeras with a more than 70% loss of OVA-OT-I 
cross priming capacity. Moreover, a strong correlation between the amount of residual CD8α + DCs and 
the ability to cross-present OVA to OT-I Tcells could be established. CD8α + DCs can develop inde-
pendently of Batf3 and in conditions of infection compensatory batf3−/− CD8α + DC development was 
reported40,41. Nevertheless, effective numerical as well as functional depletion of this subset suggests that 
any batf3-independent CD8α + DC development is not opportune for the present study setup.
Remarkably, the severe CD8α + and/or CD103+ DC cross-presentation defect did not alter athero-
sclerotic plaque phenotype in batf3−/− chimeric mice. This is in agreement with the reported lack of 
effect of TAP1 deficiency, which transports antigen-MHCI complexes to the cell surface, on plaque for-
mation in ApoE−/− mice24, albeit that the interpretation of this study was complicated by reductions in 
peripheral CD8+ Tcell numbers42. By contrast, MHCI KO mice develop 150% bigger plaques when fed a 
high fat diet for 15 weeks25. However, apart from being unable to cross-present, MHCI deficiency influ-
ences a broad range of stromal and hematopoietic cells. These mice suffer from CD8+ lymphocytopenia, 
and profound iron overload43, which can both impact atherosclerosis development22,44. Similarly, loss of 
Figure 5. Batf3 deficiency does not influence atherosclerotic plaque size. Aortic arch and root were 
dissected from wt (n = 15) or batf3−/− (n = 12) ldlr−/− mice and analyzed by histology. (a) Aortic arch and 
root were H&E stained for plaque size analysis. (b, c) Plaque area, necrotic core area and percentage necrotic 
core relative to plaque area are did not differ in the brachiocephalic artey (b) and aortic root (c). Data are 
presented as mean ± SEM.
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function studies in flt3−/− ldlr−/− mice suggested an athero-protective role of aortic CD103+ DCs, possi-
bly by increasing regulatory Tcells in the lesion26. Of note, Flt3 is involved in the development of several 
types of hematopoietic cells45, and its deficiency affects Tcells and several DC subsets systemically and 
directly as well46. Our study setup differs from the above-mentioned studies in the fact that we achieve 
specific functional targeting of cross-presenting cell populations, allowing us to evaluate for the first time 
their single contribution to atherosclerosis development.
Figure 6. Batf3 deficiency does not influence atherosclerotic plaque composition. Aortic arch and root 
were dissected from wt (n = 15) or batf3−/− (n = 12) ldlr−/− mice and analyzed by immunohistochemistry. 
(a) Representative images of Macrophages (Mac3 staining), vascular smooth muscle cells (α SMA staining), 
T cells (CD3 staining), collagen (Sirius Red staining) and apoptosis (cleaved caspase 3 staining) in the aortic 
roots of wt and batf3−/− chimeric mice. (b) Quantification of immunohistochemical stainings shown in (a). 
Data are presented as mean ± SEM.
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Even so, cross-presentation of necrotic plaque epitopes could be mediated by other cell populations, 
which were not targeted with the batf3−/− model. Therefore, subsets with reported cross-presentation 
ability such as mDCs34, pDCs35 or CD169+ macrophages36 were analyzed. PDCs are present in scarce 
amounts in the intima of atherosclerotic arteries, but their role in atherosclerosis remains inconclu-
sive47,48. The role of mDCs or CD169+ macrophages in CVD is hitherto unknown. Investigating 
cross-presentation of plaque epitopes by those cell types would require a specific mDC knockout model 
(not available to date) or combining the inducible CD169-DTR macrophage knockout model49 with 
an atherosclerosis model. Nevertheless, we did not find any relevant expansion of these populations in 
batf3−/− chimeras, rendering a compensatory effect in Batf3 deficiency unlikely.
We postulated that cross-presentation deficiency would reduce atherosclerosis by failing to induce 
cytotoxic CD8+ Tcells involved in plaque vulnerability22. However, in accordance with the unchanged 
plaque phenotype, Tcell subset numbers in blood and lymphoid organs as well as in plaques of chimeric 
batf3−/− mice were similar to those in wt controls. This suggests that CD8α + and CD103+ DCs cannot 
account for the marked increase in CD8+ Tcells in advanced atherosclerotic plaques17. In analogy to 
Cytomegalovirus infection, where priming of CD8+ Tcells is largely dependent on Batf3-cross-presentation 
Figure 7. Tcell numbers are unchanged in batf3−/− chimeras. Tcell subset numbers were analyzed in 
the aorta-draining lymph node by flow cytometry. (a) CD25+, FoxP3+ regulatory Tcells cell are presented 
relative to the CD4+ Tcell population. (b) Naïve (CD62Lhi, CD44lo), central memory (CD62Lhi, CD44hi) 
and effector memory (CD62Llo, CD44hi) populations are presented as percentages of CD8+ Tcells. (c) Naïve 
(CD62Lhi, CD44lo), and effector memory (CD62Llo, CD44hi) populations are presented as percentages of 
CD4+ Tcells. Data are presented as mean ± SEM.
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only in disease onset and not during latent infection50, cross-presentation by Batf3-dependent cells in the 
chronic stages of advanced atherosclerosis could be obsolete. In support of this view, it has been reported 
that only apoptotic cells (much more abundant in initial atherosclerotic lesions) elicit mature functional 
CD8+ Tcells51. Necrotic cells, which hallmark advanced atherosclerosis, may well fail to induce sufficient 
CD40 expression on DCs, which is an essential step to subsequent CD8+ Tcell activation. Alternatively, 
it has been shown that apoptotic tissue antigens are cross-presented to tolerize autoreactive CD8+ Tcells52 
and that sustained cross-priming by CD8α + DCs can result in tolerance53. Vaccination studies using 
tolerogenic DCs loaded with oxLDL or ApoB100 have a positive effect on atherosclerotic disease progres-
sion54,55. However, as severe CD8α + DC depletion did not increase plaque burden, a cross-tolerogenic 
role for CD8α + DCs in atherosclerosis seems unlikely.
In summary, Batf3 deficiency in hyperlipidemic conditions leads to a highly specific, severe defect in 
cross-presentation, with no effect on Tcell immunity or other leukocyte subsets. We clearly demonstrate 
that CD8α +/CD103+ DC-dependent cross-presentation does not impact atherosclerotic plaque size or 
features of plaque stability and consequently has no major causal role in plaque rupture or the genera-
tion of a cardiovascular event. Taken together, we present convincing evidence that the contribution of 
cross-presentation of atherogenic antigens to atherosclerotic plaque progression is marginal at best. Our 
study thereby raises the intriguing possibility that in advanced atherosclerosis CD8+ Tcell immunity is 
steered by other mechanisms, involving for instance Th1 Tcell activation56, which warrants further efforts 
to dissect the driving forces in cytolytic plaque-attacking Tcell generation.
Methods
RNA isolation from human atherosclerotic plaque lesions. Total RNA was extracted from 
freshly frozen atherosclerotic tissue samples obtained from endarterectomy surgery. Collection, storage 
in the Maastricht Pathology Tissue Collection (MPTC) and patient data confidentiality as well as tissue 
usage were in accordance with the “Code for Proper Secondary Use of Human Tissue in the Netherlands” 
(http://www.fmwv.nl, http://www.federa.org/sites/default/files/digital_version_first_part_code_of_con-
duct_in_uk_2011_12092012.pdf). Tissue samples destined for RNA isolation were snap-frozen imme-
diately after resection, staged by histological analysis of adjacent tissue sections according to Virmani 
et al.57 and grouped as early lesions (IT: intimal thickening/PIT: pathological intimal thickening, n = 5), 
advanced lesions (Tk/Tn FCA: thick or thin fibrous cap atheroma, n = 6) or advanced unstable lesions 
(IPH: intra plaque hemorrhage, n = 5). RNA was isolated with the Guanidine Thiocyanate (GTC)/CsCl 
gradient method and the NucleoSpin RNA II kit (Macherey-Nagel GmbH & Co. KG)58. RNA concen-
tration was determined using the Nanodrop ND-1000 (Thermo Scientific) and quality was assessed by 
RNA 6000 Nano/Pico LabChip (Agilent 2100 Bioanalyzer, Palo Alto, CA, USA) analysis based on RIN 
(RNA integration number) values. RIN values above 5.6 were considered acceptable.
RNA isolation from mouse aorta. Total RNA was extracted from freshly frozen mouse aorta. For 
early plaques 6 8 weeks old C57BL/6 mice were used, for advanced plaques 5 C57BL6 ApoE−/− mice of 
over 35 weeks old were used. Snap-frozen aorta was disrupted using Trizol (Life Technologies), glass 
beads and a Mini-Beadbeater. RNA isolation was then performed using the Qiagen RNAeasy Micro Kit 
following manufacturer’s instructions. RNA concentration and purity was determined on a Nanodrop 
2000 spectrophotometer.
Real-time PCR on human and mouse atherosclerotic plaque lesions. 500 ng total plaque RNA 
was cDNA transcribed with the iScript cDNA Synthesis Kit (BioRad) following manufacturer’s instruc-
tions. Real time PCR was performed for expression of human TAP1, ADFP, BDCA3, IRF8, Rab11b, 
Necl2 and Batf3 or mouse Rab11b, TAP1 and XCR1 using SensiMix SYBR Green (Bio-Rad) on a Bio-Rad 
CFX96 Real-Time System, C1000 Thermal Cycler. Gene expression of one housekeeping gene, i.e. human 
β -actin or mouse GAPDH, was assessed for normalization. Due to the limited quantity of plaque mate-
rial, more house-keeping genes could not be included in the analysis. Nevertheless, for analysis of plaque 
material human β -actin and mouse GAPDH are both considered stable housekeeping genes within our 
laboratory, based on various qPCR experiments to select a viable housekeeping gene for atheroscle-
rotic plaques (data not shown). Gene specific intron-spanning primers (Eurogentec) were designed with 
Roche Applied Science’s Universal ProbeLibrary Assay Design Center (Supplemental Table I). For vali-
dation of primer specificity a primer BLAST (NCBI) specificity analysis was performed. Real time PCR 
data was analyzed using Bio-Rad CFX Manager v2.0 Software.
Immunohistochemistry and colocalization on human plaque sections. The co-localization of 
the a DC marker with a marker for cross-presentation in human plaques was measured by multispectral 
imaging of immunohistochemical staining. Frozen human plaque sections were stained for CD11c (BD 
Pharmingen) and XCR1 (Novus Biologicals). From double staining, spectral imaging data sets from 
maximal three random regions of interest were taken between 420–720 nm (10 nm interval) at a 5× 
as well as at a 20× magnification using a Nuance spectral imaging system (Perkin Elmer/Caliper Life 
Sciences, Hopkinton, MA, USA) mounted on a Zeiss Axiophot microscope. Slides stained for a single 
chromogen (Vector Red and Vector Blue, both Vector Laboratories) only were used to create a spectral 
library. The spectral library was used for computational segregation of the individual image components 
www.nature.com/scientificreports/
1 1Scientific RepoRts | 5:15414 | DOi: 10.1038/srep15414
using the NuanceTM 3.0.2 software as described59. After spectral unmixing, pseudo-colors were assigned 
to unmixed images, and composite images showing co-localization were generated with the Nuance 3.0.2 
software.
Animals. All animal work was approved by the local regulatory authority of Maastricht University 
and in accordance with EU and Dutch government laws and guidelines. Mouse experiments performed 
in Cincinnati (US) complied with approved Institutional Animal Care and Use Committee guidelines 
and the guidelines of the Association for Assessment and Accreditation of Laboratory Animal Care 
International. Male ldlr−/− mice were obtained from the Jackson Laboratory (Bar Harbor, ME) and had 
been backcrossed at least 10 generations on a C57BL/6J background. For CD45.1/2 studies male ldlr−/− 
mice have been crossed in-house at our SPF breeding facility into the CD45.1 background. Batf3−/− mice 
were a kind gift from Prof. Dr. K. Hildner (Uniklinikum Erlangen, Germany) or purchased directly from 
the Jackson Laboratory. OT-I mice were a gift from Prof. Dr. M. Zenke (Uniklinikum Aachen, Germany) 
or purchased at the Jackson Laboratory and crossed to the CD45.1 (B6.SJL-Ptprca Pepcb/BoyJ) back-
ground at the Cincinnati in-house SPF mouse breeding facility. B6. PL-Thy-1a/Cy (CD90.1) mice and 
C3H Act-mOVA mice were bred in the Cincinnati in-house SPF mouse breeding facility. All mice were 
fed a standard diet (Cat# V1535, sniff Spezialdiäten GmbH, Soest, Germany) unless indicated otherwise, 
had ad libitum access to food and water and were housed under a 12 hour light-dark cycle.
Bone marrow transplantation and atherosclerosis induction in mice. Male C57BL/6 CD45.2 
ldlr−/− mice of at least 12 weeks of age were housed under filter top cages and given antibiotics supple-
mented water (Neomycin (100 mg/L; Gibco, Carlsbad, CA, USA) and Polymyxin B sulfate (60.000 U/L; 
Gibco)), starting 2 weeks before until 6 weeks after bone marrow transplantation. To induce bone mar-
row aplasia, ldlr−/− mice (n = 69) were exposed to two doses of 6 Gy total body irradiation (0.5 Gy/
min, Philips MU15F/225kV, Hamburg, Germany) one day before bone marrow transplantation, with 
12 hrs recuperation time in between each dose. Irradiated recipients (Maastricht study n = 15 wt, n = 12 
batf3−/−, Cincinnati study n = 15 for both groups, CD45.1/2 study n = 12) were injected via tail vein 
with bone marrow cell suspensions (106 cells/mouse), prepared from homozygous C57BL/6J batf3−/− 
female donor mice or wt littermate controls by tibia/ femur lavage. For the CD45.1/2 study, donor mice 
were male C57BL/6 CD45.1 ldlr−/−. For atherosclerosis induction, mice were allowed to recover for 6 
weeks after bone marrow transplantation, blood samples were taken from the tail vein and mice were 
put on a Western type diet (WTD) containing 0,25% cholesterol (Special Diets Services, Witham, Essex, 
UK) for 10 weeks. At sacrifice, mice were euthanized by a pentobarbital overdose (115 mg/kg), injected 
intraperitoneally. Blood was taken by left ventricular puncture. Spleen, aortic lymph nodes and a mix of 
peripheral lymph nodes (axillary, mesenteric, mandibular, aorta-draining lymph nodes (lnn. mediastina-
lis dorsalis, located in the precordial mediastinum: a group of two to four larger dorsal nodes attached 
to the thymus cranial to the aortic arch and lateral to the cranial caval veins) ) were isolated. For flow 
cytometry experiments, aorta and carotids were dissected before perfusion. For histological sampling, 
mice were perfused with phosphate buffered saline (PBS) (NaCl/Na2HPO4/KH2PO4, pH 7.4) containing 
sodium nitroprusside (0.1 mg/ml, Sigma) and 1% paraformaldehyde (PFA) and heart, aorta and carotids 
were dissected.
Histology and immunohistochemistry of mouse atherosclerotic lesions. After isolation, the 
carotid arteries, aorta and the heart were fixed overnight in 1% PFA and paraffinembedded sections 
(4 μ m) were cut. For frozen sections, aortic root was snap-frozen in OCT, and 4 μ m frozen sections were 
cut. To determine plaque volume and necrotic core content in the aortic arch and aortic root, plaque 
area and necrotic core were measured on four consecutive H&E stained sections at 20 μ m intervals that 
covered the entire lesion and averaged, as described before60 . In the aortic root, measurements were 
calculated for each valve separately and then added to obtain total root plaque area and necrotic core size.
Collagen content was detected by Sirius Red (Sigma) staining and expressed as a percentage of 
plaque area. Slides were analyzed in a blinded manner using a Leica DM3000 light microscope (Leica 
Microsystems, Wetzlar, Germany) coupled to a computerized morphometric system (Leica Qwin 3.5.1). 
Immunohistochemical stainings were performed on paraffin or frozen aortic root sections for CD3 
(DAKO, Glostrup, Denmark), α ‐smooth muscle actin (ASMA) (DAKO), Mac3 (BD), cleaved caspase 3 
(Cell Signaling), CD11c (supernatant of N418 Hybridoma Cells), CD8α (Thermo Scientific), biotinylated 
CD45.1 (BD Biosciences) or biotinylated CD45.2 (BD Biosciences). Slides were analyzed blindly using a 
Leica Qwin program (for ASMA and Mac3) or counted manually (for CD3 and cleaved caspase 3). The 
amount of positive cells was expressed as percentage positively stained area per total plaque area (for 
ASMA and Mac3) or as number of positive cells per mm2 plaque area (for CD3 and cleaved caspase 3).
Plasma cholesterol analysis. Cholesterol levels in plasma were measured in duplicate using a col-
orimetric assay (DiaSys, Diagnostic Systems) according to the kit’s instructions.
Flow cytometry. Blood, spleen, aortic lymph nodes and peripheral lymph nodes (a mixture of 
mesenteric, mandibular and axillary lymph nodes) were removed before perfusion, gently dissociated 
through a 70 μ m cell strainer (Greiner), treated with erylysis buffer (8.4 g NH4Cl, 0.84 g NaHCO3 in 1l 
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PBS) and stained for total leukocytes (CD45+, BioLegend), total T cells (CD3+, eBioscience), T helper 
cells (CD4+, BD Bioscience), cytotoxic T cells (CD8α +, BD Bioscience), B cells (B220+, BD Bioscience), 
NK cells (CD3− NK1.1+, BD Bioscience) monocytes (CD11bhigh Ly6Glow, BD Bioscience), granulocytes 
(CD11bhigh Ly6Ghigh, BD Bioscience), conventional dendritic cells (cDCs; CD11chigh MHCIIhigh, either 
CD8− CD11b+, double negative CD8− CD11b− or CD8+/CD103+ CD11b−, eBioscience) and plasma-
cytoid DCs (pDCs; PDCA‐1high B220+, eBioscience). T cell subtypes were analyzed performing addi-
tional cell surface staining on FoxP3 (eBioscience), CD44 (BD Bioscience) and CD62L (eBioscience). 
Cross presenting macrophages were analyzed using a cocktail of CD45 (BioLegend), CD3 (eBioscience), 
CD19 (eBioscience), CD11c (eBioscience), CD11b (BD Bioscience), F4/80 (BioLegend), and CD169 
(BioLegend), and defined as CD45+ CD3/CD19− CD11c− CD11b+ F4/80+ CD169+. For cDC and pDC 
analysis, spleen and lymph nodes were pretreated for 30 minutes with a cocktail of liberase (32 μ g/ml, 
Roche) and DNase (0.8 μ g/ml, Roche) in RPMI medium (Gibco). Absolute cell numbers in blood were 
calculated by use of Trucount tubes (BD Bioscience). All flow cytometry analysis was performed on a 
BDCanto II (BD Bioscience) using FACS Diva Analysis Software vs6.
Flow cytometry of mouse aorta. Aortic arch, carotids and thoracic aorta were dissected, trans-
ferred to an enzymatic cocktail consisting of hyaluronidase (85 U/ml, Sigma), liberase (32 μ g/ml, Roche) 
and DNase (0.8 μ g/ml, Roche) in RPMI medium (Gibco) and with forceps and syringe dissociated in 
pieces small enough to be taken up with a 1 ml Greiner pipet. Tissue was incubated in this enzymatic 
cocktail for 1 hour at 37 degrees with regular shaking and filtered through a 70 μ m cell strainer (Greiner). 
Two aortas were pooled together for consequent FACS analysis and samples were stained with a cocktail 
of CD45 (BioLegend), CD3 (eBioscience), CD19 (eBioscience), NK1.1 (eBioscience), Ly6G (eBioscience), 
F4/80 (eBioscience), CD11c (eBioscience), MHCII (eBioscience), CD45.1 (BD Biosciences) and CD45.2 
(BD Biosciences). CD3, CD19, Ly6G and F4/80 were used as dumb gate to identify CD45+CD11chigh, 
MHCIIhigh dendritic cells. Analysis was performed on a BDCanto II (BD Bioscience) using FACS Diva 
Analysis Software vs6.
OT – I cross presentation analysis. Batf3−/− or wt ldlr−/− recipient mice (n = 3– 8) on chow or 
high fat diet received intravenous 5 × 104 CFSE‐labeled (Life Technologies) purified OVA specific OT‐I/
CD45.1 CD8+ T cells together with 5 × 105 purified CD90.1 wt CD8+ T cells that served as an internal 
control. All injected CD8+ T cells were purified using the CD8+ T Cell Isolation Kit II (Miltenyi Biotec 
GmbH, Bergisch Gladbach, Germany) according to the kit’s manual. The next day, mice received i.v. 
5 × 105 irradiated (1500 rad) C3H‐actmOVA splenocytes. Three days later, spleen and lymph nodes were 
isolated and stained for CD8 (BioLegend), Vα 2 (BioLegend), CD45.1 (BD) and CD90.1 (BioLegend). 
Subsequently, OT‐I/CD90.1 proliferation and expansion were determined based on CFSE dilution and 
the ratio of OT‐I/CD45.1 to CD90.1 control CD8+ T cells.
Statistics. All data is presented as mean ± SEM. Data was processed using GraphPad Prism 5 (Graph 
Pad Software Inc., San Diego, CA, USA). Individual groups of normally distributed data were analyzed 
with a Student’s t-test, otherwise a non-parametric Mann-Whitney U test was used. Data containing 
more than two groups was analyzed with 1-way ANOVA or the non-parametric Kruksal-Wallis test, 
and results were corrected for multiple testing. Correlation analysis was performed using a Spearman 
correlation test. Different outcomes were considered significant on several levels: *p < 0.05, **p < 0.01, 
***p < 0.001.
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